{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:41:25Z","timestamp":1787586085111,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejmech.2023.116028","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T02:51:39Z","timestamp":1701917499000},"page":"116028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Small molecular CD73 inhibitors: Recent progress and future perspectives"],"prefix":"10.1016","volume":"264","author":[{"given":"Gong-hui","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-7652","authenticated-orcid":false,"given":"Fan-hao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.116028_bib1","doi-asserted-by":"crossref","first-page":"113356","DOI":"10.1016\/j.ejmech.2021.113356","article-title":"If small molecules immunotherapy comes, can the prime be far behind?","volume":"218","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib2","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/onc.2010.292","article-title":"Extracellular adenosine triphosphate and adenosine in cancer","volume":"29","author":"Stagg","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2023.116028_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00109","article-title":"A metabolic immune checkpoint: adenosine in tumor microenvironment","volume":"7","author":"Ohta","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.116028_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2016.04.001","article-title":"Immunosuppressive activities of adenosine in cancer","volume":"29","author":"Allard","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116028_bib5","series-title":"Ecto-enzyme and Signaling Functions of Lymphocyte CD 73","author":"Resta","year":"1998"},{"key":"10.1016\/j.ejmech.2023.116028_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejmech.2023.116028_bib7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.116028_bib8","first-page":"616","article-title":"Research progress on the role of adenosine pathway in tumor immunity","author":"Yu","year":"2021","journal-title":"Med. J. Chin. People\u2019s Lib. Army 6"},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2023.116028_bib9","first-page":"S27","article-title":"Suppression of inflammatory and immune responses by the A(2A) adenosine receptor: an introduction","volume":"153","author":"Palmer","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116028_bib10","doi-asserted-by":"crossref","first-page":"14711","DOI":"10.1073\/pnas.1308209110","article-title":"Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors","volume":"110","author":"Beavis","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.116028_bib11","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.str.2012.10.001","article-title":"Crystal structure of the human ecto-5'-nucleotidase (CD73): insights into the regulation of purinergic signaling","volume":"20","author":"Knapp","year":"2012","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2023.116028_bib12","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/cbic.201200426","article-title":"Crystal structure of a soluble form of human CD73 with ecto-5\u2032-nucleotidase activity","volume":"13","author":"Heuts","year":"2012","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2023.116028_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/ATVBAHA.118.311579","article-title":"CD73 (Cluster of differentiation 73) and the differences between mice and humans","volume":"39","author":"Joolharzadeh","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2023.116028_bib14","series-title":"Cell Type- and Tissue-specific Functions of Ecto-5'-Nucleotidase (CD73)","author":"Minor","year":"2019"},{"key":"10.1016\/j.ejmech.2023.116028_bib15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2217\/imt-2018-0200","article-title":"CD73: an emerging checkpoint for cancer immunotherapy","volume":"11","author":"Chen","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejmech.2023.116028_bib16","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1073\/pnas.1222251110","article-title":"CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer","volume":"110","author":"Loi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.116028_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-019-0694-x","article-title":"Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma","volume":"26","author":"Goswami","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.116028_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2023.116028_bib19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3389\/fphar.2019.00775","article-title":"The Ecto-5'-nucleotidase\/CD73 inhibitor, \u03b1,\u03b2-methylene adenosine 5'-diphosphate, exacerbates carrageenan-induced pleurisy in rat","volume":"10","author":"Caiazzo","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116028_bib20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2023.116028_bib21","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1021\/acs.jcim.0c00961","article-title":"Identification of phelligridin-based compounds as novel human CD73 inhibitors","volume":"61","author":"Lyu","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2023.116028_bib22","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1021\/acs.jmedchem.5b00802","article-title":"\u03b1,\u03b2-Methylene-ADP (AOPCP) derivatives and analogues: development of potent and selective ecto-5'-nucleotidase (CD73) inhibitors","volume":"58","author":"Bhattarai","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib23","article-title":"X-ray Co-crystal structure guides the way to subnanomolar competitive ecto-5-nucleotidase (CD73) inhibitors for cancer immunotherapy","volume":"2","author":"Bhattarai","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2023.116028_bib24","doi-asserted-by":"crossref","first-page":"11448","DOI":"10.1021\/acs.jmedchem.0c00525","article-title":"Discovery of AB680: a potent and selective inhibitor of CD73","volume":"63","author":"Lawson","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1021\/acs.jmedchem.0c01835","article-title":"Discovery of potent and selective methylenephosphonic acid CD73 inhibitors","volume":"64","author":"Sharif","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib26","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1021\/acs.jmedchem.9b01611","article-title":"2-Substituted \u03b1,\u03b2-methylene-ADP derivatives: potent competitive ecto-5'-nucleotidase (CD73) inhibitors with variable binding modes","volume":"63","author":"Bhattarai","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib27","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1021\/acsmedchemlett.0c00391","article-title":"Fluorescent probes for ecto-5'-nucleotidase (CD73)","volume":"11","author":"Schmies","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.116028_bib28","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ejmech.2018.08.035","article-title":"CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates","volume":"157","author":"Dumontet","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib29","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3389\/fphar.2020.01294","article-title":"Nucleotide analog ARL67156 as a lead structure for the development of CD39 and Dual CD39\/CD73 ectonucleotidase inhibitors","volume":"11","author":"Schaekel","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116028_bib30","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1021\/acs.biochem.9b00448","article-title":"An exceptionally potent inhibitor of human CD73","volume":"58","author":"Bowman","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.116028_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11302-019-09649-2","article-title":"Identification of adenine-N9-(methoxy)ethyl-\u03b2-bisphosphonate as NPP1 inhibitor attenuating undesired NPPase activity in human osteoarthritic chondrocytes","volume":"15","author":"Nassir","year":"2019","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejmech.2023.116028_bib32","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1021\/acs.jmedchem.9b00164","article-title":"Structure-activity relationship of purine and pyrimidine nucleotides as ecto-5'-nucleotidase (CD73) inhibitors","volume":"62","author":"Junker","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib33","series-title":"Structure Activity Relationship of 3-Methylcytidine-5\u2032-\u0391,\u03b2-Methylenediphosphates as CD73 Inhibitors, F","author":"Scortichini","year":"2020"},{"key":"10.1016\/j.ejmech.2023.116028_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104577","article-title":"4-Substituted-1,2,3-triazolo nucleotide analogues as CD73 inhibitors, their synthesis, in vitro screening, kinetic and in silico studies","volume":"107","author":"Ghoteimi","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1021\/acs.jmedchem.2c01287","article-title":"Discovery of a series of potent, selective, and orally bioavailable nucleoside inhibitors of CD73 that demonstrates in vivo antitumor activity","volume":"66","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib36","doi-asserted-by":"crossref","first-page":"10433","DOI":"10.1021\/acs.jmedchem.0c01086","article-title":"Orally bioavailable small-molecule CD73 inhibitor (OP-5244) reverses immunosuppression through blockade of adenosine production","volume":"63","author":"DU","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib37","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/jm901851t","article-title":"Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold","volume":"53","author":"Baqi","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib38","doi-asserted-by":"crossref","first-page":"6576","DOI":"10.1021\/jm300658n","article-title":"Virtual screening identifies novel sulfonamide inhibitors of ecto-5'-nucleotidase","volume":"55","author":"Ripphausen","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib39","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1016\/j.bmc.2013.08.021","article-title":"Evaluation of molecular model-based discovery of ecto-5\u2032-nucleotidase inhibitors on the basis of X-ray structures","volume":"21","author":"Furtmann","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejmech.2013.10.053","article-title":"Identification of sulfonic acids as efficient ecto-5\u2032-nucleotidase inhibitors","volume":"70","author":"Iqbal","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib41","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejmech.2016.02.073","article-title":"2-Alkoxy-3-(sulfonylarylaminomethylene)-chroman-4-ones as potent and selective inhibitors of ectonucleotidases","volume":"115","author":"AL-Rashida","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bioorg.2017.01.003","article-title":"Synthesis, characterization and biological evaluation of novel chalcone sulfonamide hybrids as potent intestinal alkaline phosphatase inhibitors","volume":"70","author":"Ejaz","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib43","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/cbdd.12861","article-title":"Isonicotinohydrazones as inhibitors of alkaline phosphatase and ecto-5\u2032-nucleotidase","volume":"89","author":"Channar","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2023.116028_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005943","article-title":"Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface","volume":"14","author":"Rahimova","year":"2018","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ejmech.2023.116028_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/13543776.2018.1407756","article-title":"Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings","volume":"28","author":"Gong","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.116028_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bioorg.2017.11.013","article-title":"4-Aminopyridine based amide derivatives as dual inhibitors of tissue non-specific alkaline phosphatase and ecto-5\u2032-nucleotidase with potential anticancer activity","volume":"76","author":"Hassan","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib47","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/acs.jcim.9b00884","article-title":"Virtual screening approach for the identification of hydroxamic acids as novel human ecto-5\u2032-nucleotidase inhibitors","volume":"60","author":"Viviani","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2023.116028_bib48","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1021\/acsmedchemlett.0c00343","article-title":"Synthesis, characterization, and in silico studies of novel spirooxindole derivatives as ecto-5\u2032-nucleotidase inhibitors","volume":"11","author":"Ashraf","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.116028_bib49","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1021\/acs.jmedchem.9b01713","article-title":"Discovery of potent and selective non-nucleotide small molecule inhibitors of CD73","volume":"63","author":"Beatty","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312745","article-title":"Generation of non-nucleotide CD73 inhibitors using a molecular docking and 3D-QSAR approach","volume":"22","author":"Bhujbal","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.116028_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200594","article-title":"Second\u2010generation CD73 inhibitors based on a 4,6\u2010Biaryl\u20102\u2010thiopyridine scaffold","volume":"18","author":"Ghoteimi","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.116028_bib52","doi-asserted-by":"crossref","first-page":"127758","DOI":"10.1016\/j.bmcl.2020.127758","article-title":"Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor","volume":"34","author":"Wang","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2023.116028_bib53","doi-asserted-by":"crossref","first-page":"116672","DOI":"10.1016\/j.bmc.2022.116672","article-title":"Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors","volume":"59","author":"Zhang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib54","first-page":"188","article-title":"Application of a fluorine strategy in the lead optimization of betulinic acid to the discovery of potent CD73 inhibitors","author":"Zhang","year":"2022","journal-title":"Steroids"},{"key":"10.1016\/j.ejmech.2023.116028_bib55","first-page":"247","article-title":"Targeting ecto-5\u2032-nucleotidase: a comprehensive review into small molecule inhibitors and expression modulators","author":"Das Neves","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116028_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115546","article-title":"Advances in CD73 inhibitors for immunotherapy: antibodies, synthetic small molecule compounds, and natural compounds","volume":"258","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:03:33Z","timestamp":1759331013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423009959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":56,"alternative-id":["S0223523423009959"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116028","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecular CD73 inhibitors: Recent progress and future perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116028"}}